Steve Bunk | Oct 26, 1997 | 6 min read
Efforts are under way to develop a vaccine against one of the world's deadliest illnesses, cervical cancer. Along with a number of university research laboratories, at least a half-dozen biotechnology and pharmaceutical companies are beginning clinical trials or are in preclinical development of such drugs. Efficacy in humans remains to be firmly established, but if the vaccines progress to later-phase trials, challenging jobs for immunologists, microbiologists, and biochemists will multiply. "